FOXO Technologies Announces Agreement With Haven Life
“The relationship between FOXO LIFE and Haven Life is a perfect fit as we grow within independent agent distribution channels,” said Wade Seward, Head of Partnership Distribution at Haven Life. “FOXO LIFE’s emphasis on improving the consumer aging experience and enhancing healthy longevity is everything we were looking for in a partner.”
About FOXO Technologies Inc. (“FOXO”)
FOXO is a technology platform company focused on commercializing longevity science into products and services that serve the life insurance industry. FOXO's epigenetic technology applies AI to DNA methylation to identify molecular biomarkers of human health and aging. FOXO seeks to modernize the life insurance industry by simplifying the consumer underwriting journey with saliva-based biomarkers and enhancing life insurance’s consumer value proposition with the FOXO Longevity Report. For more information about FOXO, visit www.foxotechnologies.com. For more information about FOXO LIFE, visit www.foxolife.com. For investor information and updates, visit https://foxotechnologies.com/investors/.
About Haven Life
Haven Life Insurance Agency, LLC (Haven Life) is re-thinking how people financially protect the ones they love. Haven Life is committed to delivering exceptional products, delightful purchasing experiences, and meaningful moments of service to the modern life insurance customer.
No Offer or Solicitation
This press release shall not constitute a solicitation of a proxy, consent or authorization with respect to any securities or in respect of the proposed transaction. This communication shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any states or jurisdictions in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such state or jurisdiction. No offering of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended or an exemption therefrom.
This press release contains certain forward-looking statements for purposes of the “safe harbor” provisions under the United States Private Securities Litigation Reform Act of 1995. Any statements other than statements of historical fact contained herein, including statements as to future results of operations and financial position, planned products and services, business strategy and plans, objectives of management for future operations of FOXO, market size and growth opportunities, competitive position and technological and market trends, are forward-looking statements. Such forward-looking statements include, but not limited to, expectations, hopes, beliefs, intentions, plans, prospects, financial results or strategies regarding FOXO and the future held by management teams of FOXO, the future financial condition and performance of FOXO and the products and markets and expected future performance and market opportunities of FOXO. These forward-looking statements generally are identified by the words “anticipate,” “believe,” “could,” “expect,” “estimate,” “future,” “intend,” “strategy,” “may,” “might,” “strategy,” “opportunity,” “plan,” project,” “possible,” “potential,” “project,” “predict,” “scales,” “representative of,” “valuation,” “should,” “will,” “would,” “will be,” “will continue,” “will likely result,” and similar expressions, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including but not limited to: (i) the risk that changes in the competitive and highly regulated industries in which FOXO operates, variations in operating performance across competitors, changes in laws and regulations affecting FOXO’s business, and changes in the combined capital structure, (ii) the ability to implement FOXO’s business plans, forecasts, and other expectations, (iii) potential inability of FOXO to establish or maintain relationships required to advance its goals or to achieve its commercialization and development plans, (iv) the enforceability of FOXO’s intellectual property, including its patents and the potential infringement on the intellectual property rights of others, and (v) the risk of downturns and a changing regulatory landscape in the highly competitive biotechnology industry or in the markets or industries in which FOXO’s prospective customers operate, including the highly regulated insurance industry. The foregoing list of factors is not exhaustive. Readers should carefully consider the foregoing factors and the other risks and uncertainties described in the “Risk Factors” filed with the SEC, and risks and uncertainties indicated in the Registration Statement, including those set forth under “Risk Factors” therein, and other documents filed or to be filed by FOXO from time to time with the SEC. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and FOXO assumes no obligation and do not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise.
Contacts / Investor Relations
Cody Slach, Matthew Hausch
Gateway Investor Relations
- 7 year-end tax tips to help you and your clients close the year successfully
- Column: Some tips for dealing with coming recession
- Reasons to pump the brakes on retirement — 6 reasons to consider delaying your retirement
- OMB moves DOL ESG rule, as backlash builds
- Americans cutting back on essential items to stave off inflation
- Corebridge Financial introduces Dimensional US Foundations Index
- Annuity or lump sum? Calculating how much a $1.9 billion Powerball win is worth
- Bank channel drives record 3Q annuity sales, LIMRA reports
- DPL partners with Corebridge Financial for commission-free annuities
- Now is a ‘perfect time’ for preretirees to consider FIAs, expert says
Health/Employee Benefits News
- Study: Mental health issues, including burnout, affecting the workplace
- Insurance subsidies to cover workers in labor disputes
- Adderall, antibiotic shortages likely to continue into 2023, Colorado pharmacist says
- Public pension debt grows as CalPERS reports even more losses
- In past recessions, firms suspended 401(k) match
- Buster Murdaugh refutes reporter’s suggestion he supports dad facing murder charges
- Consumers initiating life insurance purchases at record rate, study finds
- Laffitte defends loans he approved to Murdaugh as prosecutor grills him in bank fraud trial
- Life settlements drop 9%, but poised to pick up, Conning says
- Nassau Financial Group to acquire Delaware Life Insurance Company of New York